David Schenkein
Person ● Covered in 0 stories + Follow ✴ AI Graph Request update
David Schenkein is a General Partner at GV, where he co-leads the firm’s life science investment team and focuses on therapeutics, diagnostics, medical devices, novel care delivery systems, and payer innovation. Before joining GV, he spent ten years as chief executive officer and a member of the board of directors at Agios Pharmaceuticals, and he remains a director there. Earlier in his career, he was senior vice president of clinical hematology/oncology at Genentech, where he led medical and scientific strategies for the BioOncology portfolio, and before that he was senior vice president of clinical research at Millennium Pharmaceuticals. He is known for his long career as a hematologist and medical oncologist, for work tied to multiple oncology drug approvals at Genentech, and for overseeing the clinical development and worldwide approval of Velcade at Millennium.
Updated 4 September 2026
Public sources: gv.com
Why this page exists, and how to correct or remove it
This profile is assembled automatically because David Schenkein appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.
We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.
Claim or correct this profile Request removal How we handle personal data